BJMO - volume 12, issue 2, march 2018
W. Lybaert MD, P. Clement MD, PhD, K. Punie MD, PhD, J. Mebis MD, PhD, M. Renard , H. Wildiers MD, PhD
Chemotherapy-induced nausea and vomiting remains an important adverse effect of treatment in daily clinical practice. Recently, new data on combinations of antiemetic agents became available for the prevention of acute and delayed nausea/vomiting in patients receiving highly and moderately emetogenic chemotherapy. As a result, the leading international cancer societies updated their antiemesis guidelines. This text aims at providing guidance regarding these new regimens in the prophylaxis of chemotherapy-induced nausea and vomiting, with a particular focus on highly emetogenic chemotherapy.
Top
